$2.04
-0.08 (-3.77%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GANX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, DME Capital Management, LP, CITADEL ADVISORS LLC, Squarepoint Ops LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 6.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseaseNCT07280299Change from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score [Efficacy]Randomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: Low Dose GT-02287, High Dose GT-02287, Placebo | Parkinson Disease | 111 | 2028-06-30 | in 681 d | 2025-12-12 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's DiseaseNCT06732180Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: GT-02287 | Parkinson Disease | 20 | 2025-11-30 | — | 2025-05-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19